Long-term Treadmill Exercise Inhibits the Progression of Alzheimer's Disease-like Neuropathology in the Hippocampus of APP/PS1 Transgenic Mice
Overview
Psychology
Social Sciences
Authors
Affiliations
Previously our study has demonstrated that long-term treadmill exercise improved cognitive deficit in APP/PS1 transgenic mice of Alzheimer's disease (AD) paralleled by enhanced long-term potentiation (LTP). The present study was undertaken to further investigate whether the treadmill running could inhibit the progression of Alzheimer's disease (AD)-like neuropathology in hippocampus of the APP/PS1 mouse models of AD, and to define a potential molecular mechanism underlying the exercise-induced reduction in AD-like neuropathology. Five months of treadmill exercise resulted in a robust reduction in β-amyloid (Aβ) deposition and tau phosphorylation in the hippocampus of APP/PS1 mice. This was accompanied by a significant decrease in APP phosphorylation and PS1 expression. We also observed GSK3, rather than CDK5, was inhibited by treadmill exercise. These results indicate that treadmill exercise is sufficient to inhibit the progression of AD-like neuropathology in the hippocampus of APP/PS1 transgenic mouse model, and may mediate APP processing in favor of reduced Aβ deposition. In addition, we demonstrate that treadmill exercise attenuates AD-like neuropathology in AD transgenic mice via a GSK3 dependent signaling pathway.
Puoyan-Majd S, Parnow A, Rashno M, Heidarimoghadam R, Komaki A CNS Neurosci Ther. 2025; 31(2):e70221.
PMID: 39957598 PMC: 11831071. DOI: 10.1111/cns.70221.
Understanding the Molecular Impact of Physical Exercise on Alzheimer's Disease.
Canton-Suarez A, Sanchez-Valdeon L, Bello-Corral L, Cuevas M, Estebanez B Int J Mol Sci. 2025; 25(24.
PMID: 39769339 PMC: 11677557. DOI: 10.3390/ijms252413576.
Treadmill Exercise Facilitates Synaptic Plasticity in Mice by Regulating Hippocampal AMPAR Activity.
Yu L, Li Y, Lv Y, Gu B, Cai J, Liu Q Cells. 2024; 13(19.
PMID: 39404372 PMC: 11475322. DOI: 10.3390/cells13191608.
Nilsson J, Jiang Y, Johannesson M, Moberg M, Wang R, Fabre S Sci Rep. 2024; 14(1):21702.
PMID: 39289522 PMC: 11408627. DOI: 10.1038/s41598-024-72806-0.
GSK3: A potential target and pending issues for treatment of Alzheimer's disease.
Zhao J, Wei M, Guo M, Wang M, Niu H, Xu T CNS Neurosci Ther. 2024; 30(7):e14818.
PMID: 38946682 PMC: 11215492. DOI: 10.1111/cns.14818.